Particularly, inhibition of Nogo-B expression is effective in preventing the development of hepatocellular carcinoma, colorectal cancer and Breast cancer, indicating Nogo-B may be a possible therapeutic target for improving these cancers [54–56]. This evidence concerns the gene RTN4 and breast cancer.